NCT06218888View on ClinicalTrials.gov

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Colo-rectal Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab 200mg，D1, Q3W

DRUG

Fruquintinib

Fruquintinib 3mg ,D1-D14, Q3W

DRUG

Chidamide

Chidamide 30mg

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06218888 - A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | Biotech Hunter | Biotech Hunter